76 related articles for article (PubMed ID: 19952717)
1. KRAS status in patients with colorectal cancer peritoneal carcinomatosis and its impact on outcome.
Gillern SM; Chua TC; Stojadinovic A; Esquivel J
Am J Clin Oncol; 2010 Oct; 33(5):456-60. PubMed ID: 19952717
[TBL] [Abstract][Full Text] [Related]
2. Kras mutations and p53 overexpression in pseudomyxoma peritonei: association with phenotype and prognosis.
Shetty S; Thomas P; Ramanan B; Sharma P; Govindarajan V; Loggie B
J Surg Res; 2013 Mar; 180(1):97-103. PubMed ID: 23199549
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
4. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
5. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
6. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis.
Bouchahda M; Karaboué A; Saffroy R; Innominato P; Gorden L; Guettier C; Adam R; Lévi F
Cancer Chemother Pharmacol; 2010 Aug; 66(3):605-9. PubMed ID: 20361188
[TBL] [Abstract][Full Text] [Related]
7. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
8. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
9. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
10. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
11. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
Yen LC; Yeh YS; Chen CW; Wang HM; Tsai HL; Lu CY; Chang YT; Chu KS; Lin SR; Wang JY
Clin Cancer Res; 2009 Jul; 15(13):4508-13. PubMed ID: 19549774
[TBL] [Abstract][Full Text] [Related]
12. KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis.
Liu X; Jakubowski M; Hunt JL
Am J Clin Pathol; 2011 Feb; 135(2):245-52. PubMed ID: 21228365
[TBL] [Abstract][Full Text] [Related]
13. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.
Santini D; Loupakis F; Vincenzi B; Floriani I; Stasi I; Canestrari E; Rulli E; Maltese PE; Andreoni F; Masi G; Graziano F; Baldi GG; Salvatore L; Russo A; Perrone G; Tommasino MR; Magnani M; Falcone A; Tonini G; Ruzzo A
Oncologist; 2008 Dec; 13(12):1270-5. PubMed ID: 19056857
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
[TBL] [Abstract][Full Text] [Related]
16. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
[TBL] [Abstract][Full Text] [Related]
17. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review.
Han CB; Li F; Ma JT; Zou HW
Cancer Invest; 2012 Dec; 30(10):741-7. PubMed ID: 23075074
[TBL] [Abstract][Full Text] [Related]
18. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
19. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
20. Adenoma and carcinoma components in colonic tumors show discordance for KRAS mutation.
Hershkovitz D; Simon E; Bick T; Prinz E; Noy S; Sabo E; Ben-Izhak O; Vieth M
Hum Pathol; 2014 Sep; 45(9):1866-71. PubMed ID: 24998492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]